triciribine phosphate has been researched along with Neoplasms in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; He, Q; Jiang, Z; Ou, X; Sun, C; Zhang, H | 1 |
| Cheng, JQ; Coppola, D; Cubitt, CL; Frost, TJ; Garrett, CR; Lush, RM; Neuger, AM; Sebti, SM; Sullivan, DM; Wenham, RM | 1 |
| Drach, JC; Rosania, GR; Shedden, K; Townsend, LB | 1 |
| Ajani, JA; Benjamin, RS; Bodey, GP; Burgess, MA; Feun, LG; Krakoff, I; Lu, K; McKelvey, E; Savaraj, N; Yap, BS | 1 |
| Casper, ES; Cassidy, C; Godwin, TA; Mittelman, A; Young, CW | 1 |
| Bogden, AE; Cobb, WR; Griffin, TW; Kelton, DE; LePage, DJ; Reich, SD | 1 |
| Baker, LH; Haas, CD; Samson, MK; Schilcher, RB; Young, JD | 1 |
| Basseches, PJ; Kroschel, DM; Kvols, LK; O'Connell, MJ; Powis, G; Richardson, RL | 1 |
2 trial(s) available for triciribine phosphate and Neoplasms
| Article | Year |
|---|---|
Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.
Topics: Acenaphthenes; Adult; Biopsy; Dose-Response Relationship, Drug; Humans; Mutation; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Ribonucleotides; Treatment Outcome | 2011 |
Phase I study of tricyclic nucleoside phosphate.
Topics: Acenaphthenes; Adult; Aged; Blood Glucose; Bone Marrow; Calcium; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Parenteral; Liver; Male; Middle Aged; Nausea; Neoplasms; Phosphorus; Ribonucleotides | 1983 |
6 other study(ies) available for triciribine phosphate and Neoplasms
| Article | Year |
|---|---|
Lower endogenous p53 levels and degradation of AKT protein contribute to potent suppression of the new antibiotic Xiakemycin A on tumor cells.
Topics: A549 Cells; Acenaphthenes; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; HeLa Cells; Hep G2 Cells; Humans; Male; MCF-7 Cells; Naphthoquinones; Neoplasms; Phosphorylation; Proteolysis; Proto-Oncogene Proteins c-akt; Ribonucleotides; Tumor Suppressor Protein p53 | 2018 |
A rational approach to personalized anticancer therapy: chemoinformatic analysis reveals mechanistic gene-drug associations.
Topics: Acenaphthenes; Adenosine Kinase; Antineoplastic Agents; Biotransformation; Catalysis; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Medical Informatics; Neoplasms; Oligonucleotides; Ribonucleotides | 2003 |
Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule.
Topics: Acenaphthenes; Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Drug Evaluation; Female; Granulocytes; Humans; Hyperglycemia; Infusions, Parenteral; Leukocytes; Male; Middle Aged; Neoplasms; Ribonucleotides | 1984 |
Activity of two phase I drugs, homoharringtonine and tricyclic nucleotide, against surgical explants of human tumors in the 6-day subrenal capsule assay.
Topics: Acenaphthenes; Alkaloids; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Evaluation Studies as Topic; Harringtonines; Homoharringtonine; Humans; Kidney; Mice; Neoplasm Transplantation; Neoplasms; Ribonucleotides | 1983 |
Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5'-phosphate using a weekly intravenous regimen.
Topics: Acenaphthenes; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Humans; Injections, Intravenous; Kinetics; Liver; Male; Middle Aged; Neoplasms; Ribonucleotides; Thrombocytopenia | 1986 |
Disposition of tricyclic nucleoside-5'-monophosphate in blood and plasma of patients during phase I and II clinical trials.
Topics: Acenaphthenes; Antineoplastic Agents; Drug Evaluation; Erythrocytes; Half-Life; Humans; Kinetics; Neoplasms; Ribonucleotides | 1986 |